Evaluation of melatonin therapy on sleep and delirium in intensive care patients

ISRCTN ISRCTN47578325
DOI https://doi.org/10.1186/ISRCTN47578325
Secondary identifying numbers N0059122216
Submission date
12/09/2003
Registration date
12/09/2003
Last edited
08/09/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Richard Bourne
Scientific

STH NHS Trust
Critical Care
Royal Hallamshire Hospital
Sheffield
S10 2JF
United Kingdom

Phone +44 (0)114 271 3036
Email richard.bourne@sth.nhs.uk

Study information

Study designSingle centre randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeNot Specified
Scientific title
Study objectives1. To evaluate the effect of melatonin therapy on the sleep characteristics of intensive care patients.
2. Secondary objectives include studying the incidence of delirium and bispectral index score between patients receiving melatonin or placebo.
Ethics approval(s)South Sheffield Research Ethics Committee (UK) on 09/01/03.
Health condition(s) or problem(s) studiedNervous System Diseases: Sleep disorders
InterventionMelatonin versus placebo.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)melatonin
Primary outcome measureSleep and delirium.
Secondary outcome measuresNo secondary outcome measures
Overall study start date01/04/2003
Completion date30/04/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexNot Specified
Target number of participants48
Key inclusion criteriaPatients admitted to the adult general intensive care unit with acute respiratory failure requiring mechanical ventilation and then a tracheostomy to assist weaning.
Key exclusion criteria1. Expected length of stay of less than five further days
2. Previously treated for sleep disturbances
3. Not receiving target enteral feed volume or aspirates greater than 200mls
4. Previous history of convulsions
5. Psychiatric or neurological disease
6. Excessive alcohol consumption (equal to or greater than 50 units per week)
7. Recreational drug use
8. Sleep apnoea
9. Severe heart failure (NYHA III/ IV)
10. Sedative infusions must have been discontinued for more than 24 hours (propofol and alfentanil) or more than 36 hours (morphine and midazolam) with a Sedation Agitation Score (SAS) > 3
Date of first enrolment01/04/2003
Date of final enrolment30/04/2006

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

STH NHS Trust
Sheffield
S10 2JF
United Kingdom

Sponsor information

Department of Health (UK)
Government

Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom

Website http://www.doh.gov.uk

Funders

Funder type

Government

Sheffield Teaching Hospitals - Central Campus (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/05/2008 Yes No